Articles from Circle Pharma, Inc.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the appointment of Rob Lauzen as chief financial officer. Mr. Lauzen brings deep financial expertise and broad experience within the life sciences industry, having most recently served as chief financial officer of Prilenia Therapeutics, where he oversaw all aspects of the company’s capital strategy, finance, and investor relations functions.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today presented preclinical data related to the company’s cyclin D1 development program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data highlight the therapeutic potential of Circle Pharma’s first-in-class oral macrocyclic inhibitors to preserve retinoblastoma protein (Rb) tumor-suppressor activity by selectively blocking its interaction with cyclin D1, a key driver of cell cycle progression and proliferation in multiple hematological and solid tumor cancer types.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the preclinical anti-tumor potential of cyclin D1 RxL inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held from October 22 - 26, 2025, in Boston, MA.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the potential of CID-078 as a novel therapeutic option in pediatric cancers at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer, taking place from September 25-28 in Boston, MA. CID-078 is a first-in-class, orally bioavailable macrocyclic cyclin A/B RxL inhibitor that is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced that management will participate in two upcoming investor conferences:

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma’s oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC).

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C., May 25-28, 2025. The data, which explore the therapeutic potential of CID-078 in neuroblastoma (NB), were presented in a poster entitled:

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced that preclinical data from its lead candidate, CID-078, a first-in-class oral macrocycle cyclin A/B RxL inhibitor, has been selected for a late-breaking poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, also known as the Triple Meeting. The symposium is taking place from October 23-25, 2024, in Barcelona, Spain.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, announced today that the first patient cohort has been dosed in the phase 1 trial of CID-078, the company’s first-in-class oral cyclin A/B RxL inhibitor. The trial will evaluate CID-078 in patients with advanced solid tumors, including tumors with elevated E2F transcription factor activity, such as small cell lung cancer, triple negative breast cancer and ER+ HER-2- breast cancer following CDK 4/6-inhibitor therapy.

Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced two executive appointments as it continues to advance its MXMO macrocycle discovery platform and its oncology pipeline. Marie Evangelista, Ph.D., has been appointed Senior Vice President and Head of Cancer Biology, while Constantine Kreatsoulas, Ph.D., has been promoted to Senior Vice President and Head of Discovery Technology Sciences. These appointments align with Circle’s investments in its pipeline of macrocycle therapies, including its lead program, CID-078, currently being evaluated in a Phase 1 clinical trial in solid tumors.

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digital poster at the 2024 World Conference on Lung Cancer.

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital.

Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023, in Boston, MA.

Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and Edward Garmey, M.D., as its new consulting chief medical officer. These additions to the leadership team further bolster Circle Pharma's capabilities in oncology drug development as it advances its Cyclin A/B inhibitor program into clinical studies.

Circle Pharma announced today that two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors targeting intractable cancers. Circle expects to advance its cyclin A/B inhibitor program into IND-enabling studies later this year and subsequently into clinical development for testing in a range of cancer types, including SCLC.

Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE:PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ:GERN), vice president of oncology at Genentech (part of the Roche Group) and medical director at Pharmacia / SUGEN (acquired by Pfizer). Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent®, Perjeta®, Kadcycla®, Erivedge® and imetelstat.

Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Paul Park, MBA, as its Chief Business Officer. Mr. Park has extensive business development experience in life sciences in prior roles including vice president of business development at Ionis Pharmaceuticals, head of strategic partnerships at Aetion and various roles in international licensing, strategy and corporate development at Amgen. He joins the leadership team at Circle as the company is advancing its lead program, an orally bioavailable Cyclin A inhibitor, towards the clinic and applying its macrocycle platform to expand its pipeline which includes other targeted oncology therapeutics.

Circle Pharma, a pre-clinical stage company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, will present a poster at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-13, in New Orleans, Louisiana.

Evelyn Wang, PhD has joined Circle Pharma as its Vice President of Translational Medicine and will lead Circle’s translational team in its development of macrocycle therapeutics against intractable cancer targets.

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $66 million in an oversubscribed Series C financing.